Posted by sowhysosad on April 19, 2009, at 13:46:22
In reply to Re: Has Pristiq proven to be clinically useful? » bearfan, posted by Larry Hoover on April 19, 2009, at 8:30:04
Yeah, there are clearly people benefitting from Pristiq that couldn't tolerate Effexor. Just because it's a patent-extending, profit-maximising exercise by Wyeth, it doesn't necessarily follow that the resulting product is worthless or of dubious quaity.
Perhaps "capitalist business practices = EVIL" in some people's minds. Sure, the quest for profit does lead to some unethical behaviour amongst the drug companies, but it drives innovation too.
As I mentioned elsewhere, the UK health service (so they don't have to subsidise an on-patent drug) claim that there's no qualitative difference between citalopram and escitalopram, but escitalopram is obviously better for many people. The subtext is "oh it's a patent-extender so it must be bogus".> I wish the idea that this is a patent extender would go away. Desvenlafaxine is a specific active metabolite of venlafaxine. It's believed to be responsible for the bulk of the antidepressant effect of venlafaxine. The side effects are mostly produced by other metabolites. In simplified terms.
poster:sowhysosad
thread:891545
URL: http://www.dr-bob.org/babble/20090416/msgs/891599.html